The CMR is a population based breast imaging registry for women screened for breast cancer in NC.

The purpose of this study is to create a registry that will collect clinical data from participants attending UNC Hospitals who may present with metastatic cancer and are evaluated to receive radiation therapy. We hope to create a registry that future studies can pull from to study the impacts of radiation therapy on patient cancer outcomes.

We are conducting this study to better understand the relationship between access to care, financial stress and health related quality of life among cancer patients in NC who live in rural areas. We will be interviewing 30 rural cancer patients to learn about their cancer experience and we will be reviewing previously completed surveys about their distress and coping behaviors.

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

The purpose of this study is to evaluate and compare the survival outcome of patients with first recurrence of GBM undergoing surgical debulking/resection followed by either implantation of the SC9 device and repeat BBB opening in association with carboplatin chemotherapy or standard of care second line chemotherapy with either lomustine or temozolomide (per best physician's choice and best practice).

The primary endpoints are to determine the recommended phase 2 dose (RP2D) of SNDX-5613 administered in combination with chemotherapy in patients with relapsed or refractory KMT2A-rearranged (KMT2A-R) acute lymphoblastic leukemia (ALL), and to estimate the minimal residual disease (MRD) negative remission rate of patients with R/R infant KMT2A-R ALL treated with SNDX-5613 in combination with chemotherapy. Secondary endpoints include characterizing the pharmacokinetics (PK) of SNDX-5613 administered with chemotherapy in patients with R/R infant KMT2A-R ALL, estimating the 18-month event-free survival (EFS) of patients with R/R infant KMT2A-R ALL treated with SNDX5613 in combination with chemotherapy, estimating 18-month overall survival (OS) of patients with R/R infant KMT2A-R ALL treated with SNDX5613 in combination with hemotherapy, and characterizing the tolerability of SNDX-5613 given as monotherapy in patients with R/R infant KMT2A-R ALL. The exploratory endpoint is to assess the biologic activity of SNDX-5613 administered with chemotherapy in patients with R/RKMT2A-R ALL.

The purpose of this study is to identify specific barriers to preventing a late stage cancer diagnosis within communities identified in North Carolina as having a higher rate of advanced cancer diagnoses.

The purpose of this project is to identify and target barriers faced by rural endometrial cancer patients in order to develop a patient navigation intervention. Rural residents with endometrial cancer, the the most prevalent gynecologic cancer in the US, have higher odds of mortality than urban endometrial cancer patients. As the number of new endometrial cancer cases is expected to increase 50% by 2030, this urban-rural disparity is expected to continue widening.

The purpose of this project is to identify and target barriers faced by rural endometrial cancer patients in order to develop a patient navigation intervention. Rural residents with endometrial cancer, the most prevalent gynecologic cancer in the US, have higher odds of mortality than urban endometrial cancer patients. As the number of new endometrial cancer cases is expected to increase 50% by 2030, this urban-rural disparity is expected to continue widening.

Purpose: To develop, assess, and refine a brief electronic patient-reported outcome (ePRO) tool that can be completed weekly by patients with newly diagnosed breast and colorectal cancer to self-report progress from diagnosis to treatment initiation.